TY - JOUR
T1 - Priorities in colorectal cancer research
T2 - Recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
AU - O'Dwyer, Peter J.
AU - Eckhardt, S. Gail
AU - Haller, Daniel G.
AU - Tepper, Joel
AU - Ahnen, Dennis
AU - Hamilton, Stanley
AU - Benson, Al B.
AU - Rothenberg, Mace
AU - Petrelli, Nicholas
AU - Lenz, Heinz Joseph
AU - Diasio, Robert
AU - DuBois, Raymond
AU - Sargent, Daniel
AU - Sloan, Jeff
AU - Johnson, C. Daniel
AU - Comis, Robert L.
AU - O'Connell, Michael J.
PY - 2007/6/1
Y1 - 2007/6/1
N2 - Emerging technologies have greatly expanded our ability to detect, characterize, and treat colorectal cancer. The Coalition of Cancer Cooperative Groups convened a multidisciplinary panel, the Scientific Leadership Council in GI cancer, to discuss and advise on the priorities and opportunities to advance current and future approaches into the clinical arena to impact most rapidly the morbidity and mortality from this disease. The Council's recommendations for research priorities are the result of engagement of community and academic oncologists, patient advocacy groups, and other stakeholders including the pharmaceutical industry and governmental agencies. We detail some key prospects for investigation in the areas of colon cancer detection, prevention, and surgical and medical management. Many are in early or definitive clinical trials, and a focus on rapid accrual is urged. The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy.
AB - Emerging technologies have greatly expanded our ability to detect, characterize, and treat colorectal cancer. The Coalition of Cancer Cooperative Groups convened a multidisciplinary panel, the Scientific Leadership Council in GI cancer, to discuss and advise on the priorities and opportunities to advance current and future approaches into the clinical arena to impact most rapidly the morbidity and mortality from this disease. The Council's recommendations for research priorities are the result of engagement of community and academic oncologists, patient advocacy groups, and other stakeholders including the pharmaceutical industry and governmental agencies. We detail some key prospects for investigation in the areas of colon cancer detection, prevention, and surgical and medical management. Many are in early or definitive clinical trials, and a focus on rapid accrual is urged. The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy.
UR - http://www.scopus.com/inward/record.url?scp=34250170862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250170862&partnerID=8YFLogxK
U2 - 10.1200/JCO.2006.08.6900
DO - 10.1200/JCO.2006.08.6900
M3 - Review article
C2 - 17538178
AN - SCOPUS:34250170862
SN - 0732-183X
VL - 25
SP - 2313
EP - 2321
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 16
ER -